Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17417842 | 1.00 | TSHR (0.35) | TSHRGGPS1 | |
| SCHEMBL7053835 | 0.80 | TSHR (0.38) | TSHRGGPS1 | |
| SCHEMBL2035202 | 0.78 | GGPS1 (0.34) | TSHRGGPS1 | |
| SCHEMBL2035200 | 0.78 | GGPS1 (0.34) | TSHRGGPS1 | |
| SCHEMBL8960876 | 0.75 | TSHR (0.32) | TSHRGGPS1 | |
| SCHEMBL8960873 | 0.75 | TSHR (0.32) | TSHRGGPS1 | |
| SCHEMBL11219072 | 0.74 | GGPS1 (0.32) | GGPS1 | |
| SCHEMBL11219069 | 0.74 | GGPS1 (0.32) | GGPS1 | |
| SCHEMBL37295 | 0.72 | — | — | |
| SCHEMBL56167 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170240558-A1 | SANGUINARINE ANALOG PP2C INHIBITORS FOR CANCER TREATMENT | LIXTE BIOTECHNOLOGY, INC. (US) | 2017-08-24 | — | — | US | disclosed |
| US-20160009727-A1 | SANGUINARINE ANALOG PP2C INHIBITORS FOR CANCER TREATMENT | LIXTE BIOTECHNOLOGY, INC. (US) | 2016-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009727-A1 | SANGUINARINE ANALOG PP2C INHIBITORS FOR CANCER TREATMENT | PPP2R2A, PPP2R1A, PPP1R7 | TSHR 3335/4885GGPS1 1548/4885 |
| US-20170240558-A1 | SANGUINARINE ANALOG PP2C INHIBITORS FOR CANCER TREATMENT | PPP2R2A, PPP2R1A, PPP1R7 | TSHR 3335/4885GGPS1 1548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.